- Home
- FRES vs SCLXW Comparison
FRES vs SCLXW Comparison
Compare FRES & SCLXW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FRES
- SCLXW
- Stock Information
- Founded
- FRES 2010
- SCLXW N/A
- Country
- FRES United States
- SCLXW United States
- Employees
- FRES N/A
- SCLXW 113
- Industry
- FRES Medical Specialities
- SCLXW Biotechnology: Pharmaceutical Preparations
- Sector
- FRES Health Care
- SCLXW Health Care
- Exchange
- FRES Nasdaq
- SCLXW Nasdaq
- Market Cap
- FRES N/A
- SCLXW N/A
- IPO Year
- FRES 2020
- SCLXW 2021
- Fundamental
- Price
- FRES $0.85
- SCLXW $0.30
- Analyst Decision
- FRES
- SCLXW
- Analyst Count
- FRES 0
- SCLXW 0
- Target Price
- FRES N/A
- SCLXW N/A
- AVG Volume (30 Days)
- FRES 27.6K
- SCLXW N/A
- Earning Date
- FRES 12-31-2024
- SCLXW N/A
- Dividend Yield
- FRES N/A
- SCLXW N/A
- EPS Growth
- FRES N/A
- SCLXW N/A
- EPS
- FRES N/A
- SCLXW N/A
- Revenue
- FRES $2,341,326.00
- SCLXW N/A
- Revenue This Year
- FRES N/A
- SCLXW N/A
- Revenue Next Year
- FRES N/A
- SCLXW N/A
- P/E Ratio
- FRES N/A
- SCLXW N/A
- Revenue Growth
- FRES 94.50
- SCLXW N/A
- 52 Week Low
- FRES $0.73
- SCLXW N/A
- 52 Week High
- FRES $9.00
- SCLXW N/A
- Technical
- Relative Strength Index (RSI)
- FRES 33.72
- SCLXW N/A
- Support Level
- FRES $0.73
- SCLXW N/A
- Resistance Level
- FRES $1.47
- SCLXW N/A
- Average True Range (ATR)
- FRES 0.24
- SCLXW 0.00
- MACD
- FRES -0.04
- SCLXW 0.00
- Stochastic Oscillator
- FRES 14.95
- SCLXW 0.00
About SCLXW Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.